National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002.
about
Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety TrialAcupuncture in treating hepatic fibrosis: a review with recommendation for future studiesStimulation of hepatitis C virus (HCV) nonstructural protein 3 (NS3) helicase activity by the NS3 protease domain and by HCV RNA-dependent RNA polymeraseNIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha InterferonManaging Occupational Risks for Hepatitis C Transmission in the Health Care SettingSteatosis affects chronic hepatitis C progression in a genotype specific wayChronic hepatitis associated with GB virus B persistence in a tamarin after intrahepatic inoculation of synthetic viral RNAViral Sequence Evolution in Acute Hepatitis C Virus InfectionHuman Apolipoprotein E Is Required for Infectivity and Production of Hepatitis C Virus in Cell CultureEvaluation of Versant Hepatitis C Virus Genotype Assay (LiPA) 2.0Interaction of Hepatitis C Virus Nonstructural Protein 5A with Core Protein Is Critical for the Production of Infectious Virus ParticlesManagement of hepatitis C virus infection in HIV/HCV co-infected patients: Clinical reviewApolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature reviewImmediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis CCurrent strategies for managing providers infected with bloodborne pathogensNon invasive tools for the diagnosis of liver cirrhosis.A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment.Efficacy and tolerability of combination therapy with interferon-alfa plus ribavirin in patients with chronic hepatitis C virus infection: a single-center study in relapsers and nonresponders to previous treatment with high-dose interferon-alfa monoRandomized controlled trial of consensus interferon with or without zinc for chronic hepatitis C patients with genotype 2.Production of infectious hepatitis C virus by using RNA polymerase I-mediated transcription.Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection.Specific acquisition of functional CD59 but not CD46 or CD55 by hepatitis C virus.Spontaneous elimination of hepatitis C virus infection: a retrospective study on demographic, clinical, and serological correlatesInduction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases.Barriers to accessing care in patients with chronic hepatitis C: the impact of depression.Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection.Therapeutic challenges in hepatitis C-infected injection drug using patients.Improving noninvasive methods of assessing liver fibrosis in patients with hepatitis C virus/human immunodeficiency virus co-infection.Social support and clinical outcomes during antiviral therapy for chronic hepatitis CNaturally occurring genotype 2b/1a hepatitis C virus in the United StatesSafety of interferon beta treatment for chronic HCV hepatitis.Hepatitis C Virus Nonstructural 3/4A Protein Dampens Inflammation and Contributes to Slow Fibrosis Progression during Chronic Fibrosis In VivoLong-Term Persistent GBV-B Infection and Development of a Chronic and Progressive Hepatitis C-Like Disease in Marmosets.Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin.Chronic hepatitis C: treat or wait? Medical decision making in clinical practiceJapanese reference panel of blood specimens for evaluation of hepatitis C virus RNA and core antigen quantitative assaysSeroprevalence of hepatitis a in patients with chronic hepatitis C in isfahan province.Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection.A comparison of hepatopathologists' and community pathologists' review of liver biopsy specimens from patients with hepatitis C.Cell culture-adaptive mutations promote viral protein-protein interactions and morphogenesis of infectious hepatitis C virus
P2860
Q24683611-89CB5363-1E64-4C16-A855-C5F2C5D7E995Q26830737-9656063E-A894-4DF0-AA6D-36484E76D961Q27470016-FECC4B04-50FD-491C-8A09-17C192C478E5Q27477455-8B753AE1-B7BC-481B-BDC7-78E97CECD2D7Q27477626-DD2ACDEF-7C33-48E7-9C15-E3AF52CA0525Q27477969-D0C4200B-05BF-4E8B-B21B-44F8FAE6266FQ27478429-8D7B002E-33B1-4E69-9B9F-CDB8A74AEC9DQ27484985-803D3BE4-5904-4FA0-9458-3B66E21FCCC5Q27485012-7A971442-7AC6-47F7-9013-64BAAA7B6C5BQ27486402-E301DA5E-09E5-49FB-AFA9-F41F07A6A9A8Q27486780-0837EF59-8334-4B1F-BC80-FDB2A51C2E53Q27489337-FB440F01-04E2-4CDE-808D-C1D94C724942Q27491003-5FD8D540-9D51-4DCD-9BB8-38D1FFCD4516Q27491312-14836C0D-1342-419D-90BF-3195C259460AQ30360452-5493F72B-C60E-4966-8C3D-283659CCC88CQ30421450-19D6EE93-3A2B-41CD-91A0-1F1477BF9A45Q30540697-A94EE68A-DAA0-4DC3-A23F-08A4B522C9DAQ33739046-C1EA609A-7624-41CE-BEFD-E09357C2223AQ33788596-043BBBD4-D88E-488D-A661-4395875223B4Q33877391-F9B0E731-DADC-4AB0-BF5F-D1B552695836Q34023077-03DF0CA7-D5F4-4B20-B726-04D4D3DBCA2EQ34438382-D03DE5EE-77E9-4679-AC6F-876AFDD7772AQ34604833-842FF5C5-4984-4737-9648-B86C3F2A26BAQ34638892-07DABB87-07F3-44E4-8EB8-4DC093BC1BBFQ34913362-48E5589F-922D-4CE5-99C0-80FAA9C83182Q35065912-7A9B08AF-08D5-4762-BC04-3073EEAE488BQ35171905-D2987A20-653B-43A8-A31C-C8E41F96FDCCQ35176164-FA41E39B-A493-4502-97B4-6BF47D62E992Q35393471-7C1CE521-B3D4-42F5-9108-2DDB66816C8CQ35487437-BCDBA3B1-BE94-49C8-8846-1BA57F03AE01Q35616376-7FFADE03-6EC6-4C49-8C20-8DF878B09691Q35647851-A74C2AA5-3010-44C1-8F67-DB4344AC1F6FQ35701365-022093D9-80B8-473D-AA06-BE8B5C88742EQ35833191-F7319F2C-59C8-421C-A63B-713FC1CD5AFCQ35872101-4170C0F1-10AA-4BE4-8D75-88544E89F9DAQ36022842-016FDD81-5E29-4F86-B625-D8047CFAF5ECQ36101920-6DF1F090-49EF-48F8-9C5B-22F41895C995Q36109002-5C892229-58E4-4970-B3D3-13F59A949FE5Q36154721-F7E1BB0F-C718-478A-8417-24AFB829078CQ36155035-A2FA0A39-AB93-42A7-8DA5-511D077422C7
P2860
National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
National Institutes of Health ...... nagement of hepatitis C: 2002.
@ast
National Institutes of Health ...... nagement of hepatitis C: 2002.
@en
National Institutes of Health ...... nagement of hepatitis C: 2002.
@nl
type
label
National Institutes of Health ...... nagement of hepatitis C: 2002.
@ast
National Institutes of Health ...... nagement of hepatitis C: 2002.
@en
National Institutes of Health ...... nagement of hepatitis C: 2002.
@nl
prefLabel
National Institutes of Health ...... nagement of hepatitis C: 2002.
@ast
National Institutes of Health ...... nagement of hepatitis C: 2002.
@en
National Institutes of Health ...... nagement of hepatitis C: 2002.
@nl
P2860
P356
P1433
P1476
National Institutes of Health ...... nagement of hepatitis C: 2002.
@en
P2093
Jay H Hoofnagle
Leonard B Seeff
P2860
P356
10.1053/JHEP.2002.36992
P407
P433
P577
2002-11-01T00:00:00Z